CD276 and sarcoma: Here we set out to develop an B7-H3 directed Fc-optimized mAb for treatment of sarcomas based on the reasoning that B7-H3 is reportedly overexpressed in many solid tumors (23, 25), whereas expression in healthy tissues is limited (39, 52), and that sarcomas are NK cell-sensitive cancer types (45).